A PILOT STUDY OF PHARMACOTHERAPY (NALTREXONE) FOR HAZARDOUS DRINKING AMONG WOMEN INFECTED WITH HIV
Author(s)
Hu X*1;Weber K2;Karki M1;Cohen M3;Young M4;Thoma K5;Thomas G5;Rathore M5;Mai D4, Cook R1 1University of Florida, Gainesville, FL, USA, 2Stroger Hospital, Chicago, IL, USA, 3Stroger Hospital and Rush University, Chicago, IL, USA, 4Georgetown University Medical Center, Washington, DC, DC, USA, 5University of Florida, Jacksonville, FL, USA
OBJECTIVES: Pharmacological treatment is effective in reducing hazardous drinking in persons with alcohol dependence, while little is known whether it is effective in HIV patients. The purpose of this study was to examine feasibility and effectiveness of using pharmacotherapy (naltrexone) on women infected with HIV. METHODS: The NIAAA-sponsored pilot study was a double-blind, randomized controlled trial. Women with HIV who met criteria for NIAAA-defined past-year hazardous drinking were recruited from HIV clinical settings in Jacksonville (FL) and the Women’s Interagency HIV Study (WIHS) in Chicago (IL) and Washington DC. Participants were randomized 2:1 to oral naltrexone (50mg) or placebo for 4 months; outcomes were assessed 2, 4 and 7 months after enrollment. RESULTS: From December, 2010 to February, 2012, 19 women were enrolled (mean age 48.8 years, 95% African American). Approximately 70% of eligible women were successfully enrolled at two WIHS sites, compared with 12% at the clinical site in Jacksonville (FL). Almost all women reported prior use of other drugs (heroin, 3; methadone, 3; cocaine, 13; marijuana, 14; tobacco, 16). Among 14 (74%) women who completed the study, average daily alcohol consumption dropped significantly from 7.13 standard drinking units (SDUs) at baseline to 0.46 SDUs at month 7. CONCLUSIONS: Although the sample is small, this pilot study demonstrates the feasibility of conducting a larger study to determine the impact of naltrexone on alcohol consumption and health outcomes in women with HIV. Although enrollment of HIV-infected women into alcohol treatment trials can be challenging, we demonstrated that these challenges can be minimized by recruiting from previously established long term cohorts that directly address alcohol consumption. Health outcome, especially alcohol consumption reduction, reported in this study will provide valuable input for future decision analytical models to evaluate the cost-effectiveness of using pharmacotherapy treating hazardous drinking among HIV patients.
Conference/Value in Health Info
2013-05, ISPOR 2013, New Orleans, LA, USA
Value in Health, Vol. 16, No. 3 (May 2013)
Code
PIH4
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Infectious Disease (non-vaccine), Mental Health, Reproductive and Sexual Health